BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Pulmonary arterial hypertension clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for pulmonary arterial hypertension: 94 (53 sponsors; 19 newly posted in the last 180 days, 7 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 21.3, rank 24 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 26, Phase 3 26, Phase 4 5, N/A 34.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Insmed Incorporated INSM | 4 | P3 4 | 0 | 1 |
| Liquidia Technologies, Inc. LQDA | 5 | P3 3, P4 1, NA 1 | 1 | 1 |
| Actelion | 4 | P3 3, P2 1 | 0 | 1 |
| Tenax Therapeutics, Inc. TENX | 3 | P3 3 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 9 | P2 5, P4 2, P3 2 | 4 | 0 |
| United Therapeutics UTHR | 6 | P3 2, P2 1, NA 2, P4 1 | 2 | 2 |
| Inhibikase Therapeutics IKT | 2 | P3 2 | 1 | 0 |
| AOP Orphan Pharmaceuticals AG | 4 | NA 2, P4 1, P3 1 | 1 | 0 |
| Pulmovant, Inc. | 3 | P2 2, P3 1 | 1 | 1 |
| Pulnovo Medical (Wuxi) Co., Ltd. | 2 | P3 1, NA 1 | 0 | 0 |
| Bayer | 1 | P3 1 | 0 | 0 |
| Gossamer Bio USA, Inc. GOSS | 1 | P3 1 | 0 | 1 |
| TransThera Sciences (Nanjing), Inc. | 1 | P3 1 | 0 | 0 |
| VIVUS LLC new entrant | 1 | P3 1 | 1 | 0 |
| Eko Devices, Inc. | 3 | NA 3 | 0 | 0 |
| Gradient Denervation Technologies | 3 | NA 3 | 0 | 0 |
| Novlead Inc. | 3 | NA 3 | 1 | 0 |
| 35Pharma Inc., a GSK company | 2 | P2 2 | 0 | 0 |
| IRulya Therapeutics Inc. IRLA | 2 | P2 2 | 1 | 0 |
| NS Pharma, Inc. | 2 | P2 2 | 0 | 0 |
| Abbott Medical Devices | 1 | NA 1 | 0 | 0 |
| Aether Tech S.L. ATHR new entrant | 1 | NA 1 | 1 | 1 |
| AllRock Bio, Inc. | 1 | P2 1 | 0 | 1 |
| Apollo Therapeutics Ltd APO | 1 | P2 1 | 0 | 0 |
| Aria CV, Inc | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: VIVUS LLC, Aether Tech S.L..
Recently stopped trials
- NCT04816604 Gossamer Bio USA, Inc. - terminated: Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no l Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
- NCT07073820 Pfizer - terminated: The study terminated due to a business decision and was not based on any safety and/or efficacy concerns. A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P
- NCT01065454 Bayer - terminated: The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systol
- NCT04084678 United Therapeutics - terminated: Sponsor decision Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
- NCT05975905 Keros Therapeutics, Inc. - terminated: The study was voluntarily terminated early, following a safety review and observation of pericardial effusions. A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants W
- NCT04811092 Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA - terminated: Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previo Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
- NCT03794583 United Therapeutics - terminated: Sponsor's decision Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P2 | Tectonic Therapeutic TECX | NCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction | active not recruiting | 191 |
| 2026-12 est. | P3 | United Therapeutics UTHR | NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | enrolling by invitation | 1000 |
| 2026-12 est. | P3 | Gossamer Bio USA, Inc. GOSS | NCT06274801 Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | Pulmonary Arterial Hypertension | recruiting | 330 |
| 2026-12 est. | P2 | Pulmovant, Inc. | NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovas | recruiting | 20 |
| 2026-12-31 est. | P2/P3 | Insmed Incorporated INSM | NCT05649748 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | active not recruiting | 91 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-09 | P2 | Pfizer PFE | NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Stu | Pulmonary Hypertension | terminated | 42 |
| 2026-09-09 | P2 | Gossamer Bio USA, Inc. GOSS | NCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | terminated | 74 |
| 2026-07-31 | P1/P2 | Pfizer PFE | NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 97 |
| 2026-06-30 | P3 | Tenax Therapeutics, Inc. TENX | NCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Pulmonary Hypertension | active not recruiting | 230 |
| 2026-05-26 | P2 | Pulmovant, Inc. | NCT06635850 A Study of Mosliciguat in PH-ILD | Pulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular | active not recruiting | 135 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "pulmonary arterial hypertension"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.